In the phase II FAKTION trial with postmenopausal women who have inoperable breast cancers that are aromatase inhibitor–resistant and estrogen receptor (ER)-positive/HER2-negative, Jones et al. found that the addition of capivasertib to endocrine therapy with fulvestrant prolonged progression-free survival in these patients [169]. Here, ESR1 is linked to breast carcinoma.